CD3 Proteins-Hot targets for bispecific antibody
T cell bispecific antibodies (TCBs) are molecules that are engineered to include binding sites to the T cell receptor (TCR) and to tumor-associated or tumor-specific antigens within a single entity. One of the most widely studied TCBs in cancer immunotherapy is CD3, a molecule that has the function of stabilizing TCR structure and transmitting activation signals. To accelerate the research and development of bispecific antibodies, ACROBiosystems has developed a series of homogeneous CD3δ/CD3ε and CD3γ/CD3ε proteins with high bioactivity. These proteins are verified as a 1:1 heterodimer by nonreductive electrophoresis and MALS respectively. In addition, customer data suggests that bispecific antibody products from ACROBiosystems can be used in applications including, but not limited to clinical pharmacokinetics, therapeutic antibody screening, identification, and characterization.